Lexicon Pharmaceuticals (LXRX) Short term Debt (2010 - 2025)

Lexicon Pharmaceuticals (LXRX) posted quarterly Short term Debt of $4.6 million for Q4 2025, down 89.07% quarter-over-quarter from $42.1 million in Q1 2025.

Lexicon Pharmaceuticals (LXRX) Short term Debt (2010 - 2025) Analysis & Trends

Lexicon Pharmaceuticals (LXRX) has reported Short term Debt for 13 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Short term Debt changed N/A year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at $4.6 million (changed N/A YoY), while the FY2025 annual figure was $4.6 million, changed N/A from the prior year.
  • Short term Debt declined to $4.6 million in Q4 2025 per LXRX's latest filing, from $42.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $42.1 million in Q1 2025 and bottomed at $4.6 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Lexicon Pharmaceuticals 1.04 Bn 846.13 Mn 653,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 4.60 Mn
Mar 31, 2025 42.06 Mn
Sep 30, 2021 11.69 Mn
Jun 30, 2021 11.68 Mn
Mar 31, 2021 11.66 Mn
Dec 31, 2020 11.65 Mn
Sep 30, 2020 8.69 Mn
Jun 30, 2020 10.46 Mn
Mar 31, 2020 10.73 Mn
Dec 31, 2019 11.01 Mn
Sep 30, 2019 11.29 Mn
Jun 30, 2019 1.12 Mn
Mar 31, 2019 1.12 Mn
Dec 31, 2018 1.12 Mn
Sep 30, 2018 1.12 Mn
Jun 30, 2018 12.90 Mn
Mar 31, 2018 13.52 Mn
Dec 31, 2017 14.09 Mn
Sep 30, 2017 14.63 Mn
Jun 30, 2017 15.16 Mn